Hepatitis
News
Dental, obstetrics, and gynecology residents have highest NSI rate
Conference Coverage
New regimen for hepatitis C genotype 2 beats previous standard of care
A two-drug regimen without ribavirin was found superior to the current standard of care for genotype 2 (GT2) hepatitis C virus infection,...
News
New antivirals, more screening could slash hepatitis C cases
Hepatitis C could be reduced by 90% or more in the United States by the year 2040 with the use of direct-acting antivirals, near-universal...
News
ELF the most effective mortality predictor for coinfected HIV, HCV patients
A new study concluded that enhanced liver fibrosis (ELF) was significantly more effective than were APRI and FIB-4 at predicting all-cause...
Conference Coverage
Proportion of HCV patients in U.S. with cirrhosis climbing
Key clinical point: Despite a national decline in the prevalence of hepatitis C virus infection, the prevalence of cirrhosis among HCV-infected...
News
Short-course DAA regimens for HCV provide limited cure rates
Four weeks of three- or four-agent direct-acting antiviral therapy was well tolerated, but less than a third of non-cirrhotic patients with...
Conference Coverage
ARC-520 shows promise in chronic hepatitis B
ARC-520, the first RNA interference–based drug to reach patients, produced deep and durable knockdown of viral antigens and DNA in chronic...
Conference Coverage
VIDEO: U.S. hepatitis C treatment capacity falls short of need
Despite new hepatitis C treatment options, the health care system’s capacity to treat patients still falls far short of what’s needed.
Conference Coverage
AASLD: HCV cure associated with reduction in all-cause mortality
Sustained virologic response in patients with hepatitis C virus infection is associated with large reductions in all-cause mortality and appears...
Conference Coverage
AASLD: Pilot study shows value of response-guided therapy for HCV GT1b
Response-guided therapy using all-oral triple direct-acting antiviral therapy appears useful for shortening the duration of treatment in...
Conference Coverage
Elevated liver cancer risk after HCV cure may justify surveillance
Sustained virologic response in patients with well controlled hepatic C virus infection does not protect select subgroups of this cohort from...